Saturday 17 October 2026
Export TYRA’s income statement to Excel — free account
Tyra Biosciences, Inc.
TYRA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 46.8% and free cash flow fell 31.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
18.52
0.52
−2.73%
Follow TYRA
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 11.37 | 4.93 | 6.55 | 11.24 | 6.42 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 31.36 | 14.27 | 19.74 | 29.60 | 26.41 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 16 | 25 | 38 | 49 | 60 | 87 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | — | — | (4) | (9) | (26) | (55) | (69) | (86) | (120) | |||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | — | (4) | (9) | (26) | (55) | (69) | (86) | (120) | |||||
| Depreciation | — | — | — | 0 | 0 | 0 | 0 | 0 | 1 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | (0.10) | (6.05) | (1.91) | (1.32) | (1.62) | (1.51) | (2.01) | |||||
| Cash flow | — | — | — | (0.06) | (5.03) | (1.72) | (1.20) | (1.17) | (1.22) | (1.60) | |||||
| Capex | — | — | — | 0.00 | (0.20) | (0.05) | (0.01) | (0.02) | (0.01) | 0.00 | |||||
| Free cash flow | — | — | — | (0.06) | (5.24) | (1.77) | (1.21) | (1.19) | (1.23) | (1.60) | |||||
| Book value | — | — | — | (0.11) | (8.84) | 21.90 | 6.16 | 4.78 | 6.00 | 4.35 | |||||
| Shares, m | — | — | — | 43 | 2 | 14 | 42 | 43 | 57 | 60 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (3) | (8) | (24) | (50) | (50) | (70) | (95) | ||||
| Capex | — | — | — | 0 | 0 | (1) | (1) | (1) | (1) | 0 | |||||
| Free cash flow | — | — | — | (3) | (8) | (24) | (51) | (51) | (70) | (95) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | (5) | 13 | 300 | 252 | 196 | 333 | 247 | ||||
| Total debt | — | — | — | 0 | 28 | 1 | 3 | — | — | — | |||||
| Net debt | — | — | — | 0 | (15) | (302) | (251) | (203) | (341) | (256) | |||||
| Shareholders’ equity | — | — | — | (5) | (14) | 302 | 258 | 204 | 343 | 259 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | (1,539.77) | (112.90) | (16.30) | (19.31) | (28.10) | (29.34) | (37.13) | ||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | (556.67) | (6,300.84) | (3,807.64) | (2,614.25) | |||||
| ROE | — | — | — | 44.24 | 101.59 | (18.25) | (19.77) | (29.92) | (31.60) | (39.83) | |||||
Negative figures in brackets.
Charts ten years each
Tyra Biosciences, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| AAPG Ascentage Pharma Group International - Unsponsored ADR | $1.4B | — | — | — | — | +17.74% (above 0%: growing) | — | — | Compare |
| OMER Omeros Corporation | $1.4B | 9.5× | 2.1× | +35.46% (above 0%: growing) | n/m | +118.70% (above 0%: growing) | 97.20% | 0.26% | Compare |
| INBX Inhibrx Biosciences, Inc. | $1.3B | — (loss-making) | — (loss-making) | +992.44% (above 0%: growing) | n/m | +0.12% (above 0%: growing) | 100.00% | 0.00% | Compare |
| ORIC Oric Pharmaceuticals, Inc. | $1.3B | — (loss-making) | — | — | n/m | −3.42% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| TYRA Tyra Biosciences, Inc. | $1.3B | — (loss-making) | — | — | n/m | −31.34% (below 0%: shrinking) | 0.00% | 0.00% | |
| GHRS GH Research PLC | $1.3B | — (loss-making) | — | — | n/m | −66.62% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| NKTR Nektar Therapeutics | $1.3B | — (loss-making) | — (loss-making) | −9.34% (below 0%: shrinking) | n/m | −65.73% (below 0%: shrinking) | 100.00% | (417.94%) | Compare |
| DRTS Alpha Tau Medical Ltd. | $1.2B | — (loss-making) | — | — | n/m | −30.42% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| SNDX Syndax Pharmaceuticals, Inc. | $1.2B | — (loss-making) | — (loss-making) | +91.76% (above 0%: growing) | n/m | +65.47% (above 0%: growing) | 95.59% | (54.95%) | Compare |
| Median of peers | $1.3B | — | — | +63.61% | — | −1.65% | 95.59% | 0.00% |
Tyra Biosciences, Inc. (TYRA) key facts
- Concern: Tyra Biosciences, Inc. reported a net loss of $119.9 million, or a loss of $2.01 per share, for fiscal 2025.
- Tyra Biosciences, Inc. (TYRA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, TYRA traded at $18.52, a market capitalization of $1.3 billion.
- Return on equity was −39.8% and debt-to-equity 0.00.